信迪利单抗
信迪利单抗（Sintilimab，商品名达伯舒）是一种用于治疗霍奇金淋巴瘤的PD-1抑制剂，[2]并已在中国获得NMPA批准上市，[3]它是一种完全人源化IgG4单克隆抗体 [4]，可与程序性死亡蛋白1（PD-1）结合。[5]该药由苏州信达生物[6]和礼来联合开发。[7]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | PD-1 |
| 臨床資料 | |
| 商品名 | 达伯舒 |
| 其他名稱 | IBI308[1] |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 2072873-06-2 |
| UNII | |
临床应用
副作用
临床研究
目前，该药正在进行20多项有关于其他适应症的临床试验，以评估信迪利单抗在单药或与其他药物联合应用治疗各种实体肿瘤的临床疗效[10]。2019年1月，信迪利单抗的有关治疗复发性霍奇金淋巴瘤的临床试验结果发表。[8]
参考文献
- ^ anti-PDCD1 monoclonal antibody IBI308 - National Cancer Institute. National Cancer Institute. [2019-09-08]. （原始内容存档于2020-10-14）.
- ^ Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026. Reuters. October 24, 2018. （原始内容存档于2019-11-29）.
- ^ NMPA Approves Tyvyt For Hodgkin's lymphoma Read more from Asian Scientist Magazine. Asian Scientist Magazine. January 9, 2019 [2019-09-08]. （原始内容存档于2020-08-20）.
- ^ OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer. Journal of Thoracic Oncology. [Dec 1, 2018].
- ^ 5.0 5.1 SM Hoy. Sintilimab: First Global Approval. - NCBI. Drugs (National Center for Biotechnology Information). 11 February 2019, 79 (3): 341–346. PMID 30742278. doi:10.1007/s40265-019-1066-z.
- ^ Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company. SEC.gov. December 20, 2018. （原始内容存档于2019-04-24）.
- ^ Sintilimab - Eli Lilly/Innovent Biologics - AdisInsight - Springer. Springer. 28 Mar 2019. （原始内容存档于2019-04-24）.
- ^ 8.0 8.1 Stephen M. Ansell. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma. The Lancet. Jan 1, 2019.
- ^ A first-in-human phase 1a trial of sintilimab (IBI308). American Society of Clinical Oncology. 12 October 2019. （原始内容存档于2019-04-24）.
- ^ Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection). The New York Times. [Feb 22, 2019]. （原始内容存档于2019-03-07）.